Sheffield is the premier centre in the UK for bone oncology, with an international reputation for clinical and translational research. Working with major pharma companies, Sheffield-led trials have been key to the registration of bisphosphonates, RANK ligand inhibitors and Radium-223.
Sheffield DNA repair research was key to the development of PARP inhibitors, now licensed for advanced BRCA mutated ovarian, breast and prostate cancer. These agents continue to be assessed worldwide, including in the ECMC network, in a variety of clinical settings.
Sheffield ECMC has designed and delivered a number of early phase clinical trials for patients with thoracic malignancies. Sheffield also leads several early phase clinical trials of improved radiotherapy delivery for non-small cell lung cancer. We are a world-leader in inhaled gas MRI, which provides clinically relevant functional information for lung cancer radiotherapy.
Sheffield Trophoblastic Treatment Centre is one of two national designated treatment centres for the management of Gestational Trophoblastic Disease, registering 500 patients/year. We also lead clinical trials in bladder cancer, melanoma, sarcoma and thyroid cancer and we are a European centre of excellence for neuroendocrine tumours.
Advanced cellular therapies